

REMARKS

Currently claims 1-27 are pending. Claims 21, 23-24 are cancelled. Claim 27 is new. The claims have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Robert H. Brink
Attorney for Applicants
Registration No. 36,094

Date: *17 December 2004*
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-3323
Facsimile: 919-483-7988

PF4813USW

ABSTRACT

A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

